Will the markov.bio AI copilot for drug discovery be influential in the R&D of a marketed drug? (Before 2030)
7
67
170
2030
14%
chance

markov.bio is developping an "AI copilot for early-stage drug discovery."

Will this product be credited for influential discoveries during early-stage developement of a drug that makes it to market?

Makes it to market: approved for human use by the FDA or EMA.

Credited: at least one press report, scientific publication, blog post, public statement from the drug manufacturer (not from markov.bio) that the product was influential during the developement of the drug. Testimony or interview of a member of the early stage developement team would also count if from a reliable outlet (enpts, C&EN,...).

Influential: essential to a discovery, or accelerated a discovery significantly, or reduced costs significantly.

Resolves No instantly if markov.bio folds or otherwise cease operation in the early stage drug discovery sector (so, exposure to founder's possible lack of buisness sense even if the science is fine).

I reserved the right to resolves N/A on ambiguity after discussion in the comment (I foresee possible claims regarding ambiguity in the "influential" claim)

Get Ṁ200 play money
Sort by:
bought Ṁ100 of NO

Never heard of them and the field is IMHO thick on promises and thin on anything that even resembles a working product. Also, the 2030 date for getting to market is very tight. (e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1299137/ has 12 years on average from pre-clinical tests to approval). So even if they already did help in a discovery of a drug, it is not very likely it would be approved by 2030.

bought Ṁ3 of YES

Never heard of them but I think the field is promising

More related questions